Clinical pathways

What is the programme and its aims?
Our ambition is to improve cancer outcomes for patients linking commissioners and providers to improve delivery of cancer care across the East Midlands. The project on high value healthcare will support the development of sustainable, high quality healthcare services, whilst maximising the relationship between the healthcare resources put in and the health benefits realised. Patients across the East Midlands will have access to optimised care along a standardised, evidence-based, high value pathway for their disease.

Why is the programme required?
Within the region, there is evidence of variation in clinical practice and inequalities in access and outcomes. These included gaps in service provision, particularly for support for patients living with and beyond cancer. There was also evidence of significant variations in the likelihood of following a curative or palliative arm of the pathway, according to age, gender and diagnosing trust.

Who are the partners?
We are working in close partnership with the local providers and clinical commissioning groups.

How are we making a difference?
We have developed a standardised, evidence based high value care pathway for oesophageal and gastric cancers in the year 2014/15, after recognising significant variation in regional outcomes, cost and clinical practice. The pathway – for nineteen clinical commissioning groups and eight providers – will optimise care across the region, ensuring consistent and high quality support is available to all patients within the East Midlands, no matter where they live. The project has been accepted as part of the NHS England Accelerate, Coordinate, Evaluate (ACE) programme, which focuses on improving early diagnosis.

Further to the above, an additional four pathways have been developed and agreed for prostate, breast, colorectal, and lung, details for which can be found in the East Midlands Inter Provider Transfer Guidance below.

What’s next?
We are currently working closely with our partners to develop standardised, evidence-based best practice pathway for head and neck cancer.

What are the key resources?
pdfInter Provider Transfer Guidance

Who to contact for further information?
This email address is being protected from spambots. You need JavaScript enabled to view it., Senior Quality Improvement Manager